April 30, 2021 8:40 am
The Johnson and Johnson vaccine is not the only one to have raised concerns about rare blood-clotting events. So, what changes now?
April 22, 2021 12:29 pm
The regulators for the Food and Drug Administration said that the company manufacturing the vaccine, Emergent BioSolutions, may have contaminated additional doses at the plant. They said the company failed to fully investigate the contamination.
April 20, 2021 12:59 pm
While Russia's Sputnik V vaccines are due to arrive this month or latest by next month, manufacturers like Moderna and Johnson and Johnson have been urged to seek emergency use approval in India.
April 05, 2021 10:41 am
J&J said it was "assuming full responsibility" of the Emergent BioSolutions facility in Baltimore, reiterating that it will deliver 100 million doses to the government by the end of May.
February 26, 2021 9:33 pm
If cleared for emergency use, the J&J vaccine would offer a one-dose option that could help speed vaccinations, tamp down a pandemic that has killed more than 500,000 people in the U.S. and stay ahead of a mutating virus.
February 25, 2021 2:09 pm
The US Food and Drug Administration (FDA) has said that the single-dose vaccine for Covid-19 manufactured by Johnson & Johnson is safe and effective against the novel coronavirus. How does the shot work?
January 30, 2021 8:21 pm
The vaccine, developed at J&J’s Janssen Pharmaceutical Companies, will be the first single-dose vaccine introduced for commercial use, once cleared for emergency use.
October 19, 2020 12:49 pm
After Oxford-AstraZeneca, Johnson & Johnson has now paused its vaccine trials — again on account of illness in a participant. Since both use the same platform, is this a pattern, or is it likely a coincidence?
October 22, 2020 1:07 pm
Johnson & Johnson became the second company after AstraZeneca to halt Covid-19 vaccine trials. Last month, Oxford vaccine trials were halted after one of the participants in the UK developed an "unexplained illness".
October 13, 2020 11:09 am
Both stock indexes are close to erasing year-to-date losses, supported by inflows of around $580 million into Indian equities from foreign investors this month.